已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and Safety of Combination Therapy with PARP Inhibitors and Anti-Angiogenic Agents in Ovarian Cancer: A Systematic Review and Meta-Analysis

医学 荟萃分析 卵巢癌 肿瘤科 癌症 内科学 药理学
作者
István Baradács,Brigitta Teutsch,Ádám Vincze,Péter Hegyi,Bence Szabó,Péter Nyírády,Nándor Ács,Zsolt Melczer,Ferenc Bánhidy,Balázs Lintner
出处
期刊:Journal of Clinical Medicine [Multidisciplinary Digital Publishing Institute]
卷期号:14 (5): 1776-1776 被引量:2
标识
DOI:10.3390/jcm14051776
摘要

Introduction: Ovarian cancer is a significant contributor to gynecological cancer-related mortality, necessitating innovative treatment strategies. This systematic review and meta-analysis aimed to assess the efficacy and safety of combining PARP inhibitors with anti-angiogenic agents (AAAs) in the treatment of ovarian cancer. Methods: This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and was registered on PROSPERO (CRD42022319461). A systematic search of three electronic databases, including MEDLINE (via PubMed), EMBASE, and Cochrane Library was conducted to identify relevant randomized controlled trials (RCT) that evaluated the efficacy and safety of the combination therapy. Subgroup analyses were based on BRCA mutation status. Meta-analysis was conducted to estimate pooled hazard ratios (HR) and risk ratios (RR) for progression-free survival (PFS) and adverse events, respectively. The combination therapy was compared to PARP inhibitors alone and to chemotherapy. Heterogeneity was assessed using Higgins and Thompson’s I2 statistic where applicable. Results: Seven RCTs involving 2397 patients were included. Combination therapy did not show a statistically significant improvement in PFS compared to PARP inhibitor monotherapy in the general population (HR 0.63, CI 0.37–1.06), or in BRCA-mutated (HR 0.70, CI 0.30–1.63) and BRCA wild-type subgroups (HR 0.39, CI 0.14–1.07). When compared to chemotherapy, combination therapy produced no significant PFS benefit in recurrent ovarian cancer (HR 0.83, CI 0.42–1.63) in the total population. Safety analysis revealed that hypertension and diarrhea were significantly more frequent in combination therapy compared with PARP inhibitors alone (RR 6.80, CI 2.87–16.06 and RR 10.04, CI 2.25–44.75) or chemotherapy alone (RR 13.80, CI 3.43–55.57 and RR 6.57, CI 2.84–15.24). Conclusions: The combination of PARP inhibitors and AAAs did not demonstrate a statistically significant benefit in PFS compared to PARP inhibitors or chemotherapy alone in recurrent ovarian cancer. While the combination therapy was generally well tolerated, hypertension and diarrhea occurred significantly. These findings suggest that combination therapy may not provide a clear survival advantage in the recurrent setting. Further high-quality, biomarker-driven clinical trials are needed to refine patient selection, optimize toxicity management, and determine the potential role of combination therapy in ovarian cancer treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
立春发布了新的文献求助10
2秒前
深情安青的应助被ForTune采纳,获得10
3秒前
ket的应助被ljxx采纳,获得10
3秒前
Maestro_S的应助被开心德地采纳,获得10
3秒前
研友_LwlNdn的应助被ForTune采纳,获得10
3秒前
壳聚糖完成签到 ,获得积分10
4秒前
科研通AI6.3的应助被ForTune采纳,获得10
4秒前
斯文败类的应助被ForTune采纳,获得10
4秒前
机智的白卉的应助被ForTune采纳,获得10
4秒前
化学小猪完成签到,获得积分10
4秒前
4秒前
5秒前
almost发布了新的文献求助10
6秒前
烟花的应助被yts8885采纳,获得10
7秒前
7秒前
8秒前
8秒前
8秒前
8秒前
8秒前
9秒前
zhang发布了新的文献求助10
9秒前
10秒前
flyboy发布了新的文献求助10
10秒前
化学小猪发布了新的文献求助10
10秒前
10秒前
yts8885发布了新的文献求助10
10秒前
春风暮雪发布了新的文献求助10
11秒前
自由沂完成签到 ,获得积分10
13秒前
yts8885发布了新的文献求助10
14秒前
gchycc完成签到 ,获得积分10
14秒前
yts8885发布了新的文献求助10
14秒前
yts8885发布了新的文献求助10
14秒前
yts8885发布了新的文献求助10
14秒前
yts8885发布了新的文献求助10
14秒前
秋风的应助被852采纳,获得10
14秒前
14秒前
15秒前
赘婿的应助被dxftx采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184686
求助须知:如何正确求助?哪些是违规求助? 9573640
关于积分的说明 21832630
捐赠科研通 7782020
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558513
邀请新用户注册赠送积分活动 2481010